Life science tools · Lab automation software
Infera
A two-person team out of Y Combinator’s Spring 2026 batch wants scientists to describe an experiment in plain English and have Infera turn it into an instrument-ready run on the liquid handlers, thermocyclers and other machines a lab already owns. The company is weeks old by public record standards: no clinical trials, no FDA filings and no confirmed financing disclosed yet.
The pitch
“Labs run on hardware from the future and software from the past,” Infera’s founders wrote in their Y Combinator launch post. The instruments themselves are not the problem. Mass spectrometers identify thousands of proteins, flow cytometers read tens of thousands of cells a second and cryo electron microscopes image at near atomic resolution. What sits around those machines, in the founders’ telling, is a patchwork of vendor-specific software that has not changed much since the early 2000s.
Infera positions itself as a translation layer. A scientist writes an experiment the way they would explain it to a colleague. The system asks clarifying questions, checks the description against a lab’s inventory and instrument state, and then generates the vendor-specific scripts needed to run it on programmable equipment. For manual steps, such as pipetting, gels or hand fermentation, the company says it functions as a context layer instead, tracking which step a person is on and what could go wrong.
“Infera is the Claude Code for scientific instruments,” the company says of itself, an analogy aimed at researchers who have watched coding assistants turn plain instructions into working software and want the same thing for wet lab work.
The problem it names
“We’ve watched labs running ~6 instruments from 3+ vendors write a one-off script for every experiment, stitch outputs together by hand, and track inventory in a Google Sheet someone probably forgot to update last Tuesday. Scientists spend their week being human glue between machines that should already talk to each other,” the founders wrote. It is a company-stated description of the problem, not an independently measured one, but it matches a familiar complaint in life science tooling circles: that lab informatics has lagged far behind the instruments it is meant to serve.
On its website, Infera says it is hardware-agnostic and lists specific liquid handling platforms it already works with. “No. Infera runs on the instruments you already have, like Opentrons, Hamilton, and Tecan. We translate your protocols into the scripts each one expects. Nothing to buy, nothing to rip out,” the site states in answer to a frequently asked question about whether labs need new hardware. The site also lists thermocyclers as a supported instrument category, though it does not name specific thermocycler models the way it names the three liquid handler vendors.
Founders
“Founded by Chloe Sow and Troy Zhang, Infera helps you control lab instruments with natural language,” Menlo Times wrote in a roundup of that week’s Y Combinator launches. According to the company’s own account, Chloe Sow studied mechanical engineering at Harvard and had already been building research software and medical devices before college, including as a Regeneron Science Talent Search Scholar and the developer of a microfluidic device for detecting harmful chemicals in household products. The company says she has done research at Fred Hutch, Brigham and Women’s, Harvard Medical School and Pacific Northwest National Lab.
Troy Zhang studied computation and neural systems at Caltech, where the company says he held an endowed research fellowship as an undergraduate, published two first-author cancer papers, holds a first-inventor agtech patent, and built and sold two companies before Infera. None of those individual claims, the fellowship, the papers, the patent or the prior exits, were independently verified in this research; they come from the company’s own biography on its Y Combinator launch post. A stealth-startup tracking account on the social platform X did independently flag Troy Zhang’s emergence with a new company: “Troy Zhang comes out of stealth mode and debuts Infera,” it posted on August 7, 2026, linking to a LinkedIn profile under the handle troyzh.
“Between us, we’ve run experiments by hand, written the scripts, and watched the whole system break when one person leaves. That’s the problem we’re building Infera to fix,” the founders wrote, framing the company as built from their own lab experience rather than an outside read on the market.
A young company’s timeline
Infera was founded in 2026 and joined Y Combinator’s Spring 2026 batch, internally labeled P26. The company’s Launch YC post went live in the first half of 2026, and it appeared in Menlo Times’ roundup of that week’s Y Combinator launches alongside four other early-stage startups. On its site, the company says: “Harvard + Caltech team, YC P26, out to bring real automation to every wet lab.” It also says it is “onboarding a handful of labs as pilots” and, in its launch post, that it is “currently running pilots with Boston-area academic labs and cores,” inviting introductions from PIs, core directors, other YC founders with wet labs, and instrument manufacturers. No pilot lab, core facility or manufacturer partner is named in any source reviewed for this profile.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Accelerator admission | Listed by Y Combinator as a Spring 2026 (P26) batch company, founded 2026, based in San Francisco, team size 2, status active. | Independent |
| Supported instruments | Company site names Opentrons, Hamilton and Tecan liquid handlers as already supported, plus a thermocycler category with no models named. | Company-stated |
| Named lab customers | None found. The company describes unnamed pilots with academic labs and cores in the Boston area and says it is onboarding “a handful of labs.” | Not found |
| Founder credentials | Regeneron STS Scholar status, an endowed Caltech fellowship, two first-author cancer papers, an agtech patent and two prior company exits are all as described by the founders; none were independently confirmed in this research. | Company-stated |
| Independent sighting | A stealth-startup tracking account on X noted Troy Zhang’s public debut of Infera on August 7, 2026, and linked to a LinkedIn profile under his name. | Independent |
| SEC Form D | No Form D was found for this Infera. An EDGAR filer named “Infera Health, Inc.” (CIK 0002061090) filed a Form D in March 2025, but that filer is a Los Angeles and Cambridge based medical device compliance software company with different officers, Charles Blumsack and Amanda Herson, and is not this company. | Not found |
| FDA, trials, NIH, NSF, PubMed | No records found under this company’s name in any of those registries, consistent with a software company that does not develop a regulated device or drug. | Not found |
Read plainly: what is public and confirmed is that Infera exists, was admitted to Y Combinator’s Spring 2026 batch, is run by two named founders, and describes a specific list of liquid handling instruments it already supports. Everything else, from the founders’ individual credentials to any pilot lab’s identity to any dollar figure raised, currently rests on the company’s own account, with no independent confirmation found in this research.
What to watch
- Whether Infera names a pilot lab, core facility or instrument manufacturer partner, which would move the customer story from claimed to documented.
- A first SEC Form D under Infera’s own name or its likely Delaware entity, which would confirm outside investment beyond the standard Y Combinator accelerator deal.
- Whether the list of supported instrument vendors grows beyond Opentrons, Hamilton and Tecan, or whether named thermocycler models appear.
- Independent, on-the-record confirmation of the founders’ stated academic and professional history.
In their words
“Labs run on hardware from the future and software from the past.”
Infera, Y Combinator launch post, 2026 · Company-stated
“We’ve watched labs running ~6 instruments from 3+ vendors write a one-off script for every experiment, stitch outputs together by hand, and track inventory in a Google Sheet someone probably forgot to update last Tuesday.”
Infera, Y Combinator launch post, 2026 · Company-stated
“Between us, we’ve run experiments by hand, written the scripts, and watched the whole system break when one person leaves. That’s the problem we’re building Infera to fix.”
Chloe Sow and Troy Zhang, co-founders, Y Combinator launch post, 2026 · Company-stated
“No. Infera runs on the instruments you already have, like Opentrons, Hamilton, and Tecan. We translate your protocols into the scripts each one expects. Nothing to buy, nothing to rip out.”
Infera, company website FAQ, accessed Sep 25, 2026 · Company-stated
“Harvard + Caltech team, YC P26, out to bring real automation to every wet lab.”
Infera, company website FAQ, accessed Sep 25, 2026 · Company-stated
“Founded by Chloe Sow and Troy Zhang, Infera helps you control lab instruments with natural language.”
Menlo Times, Y Combinator launches roundup, 2026 · Independent
“Troy Zhang comes out of stealth mode and debuts Infera”
Stealth Startup Spy, X, Aug 7, 2026 · Independent
Related companies
Sources
- IndependentInfera company listing, Y Combinator directory
- CompanyLaunch YC: Infera, Control Lab Instruments with Natural Language
- CompanyInfera company website, home and FAQ pages
- IndependentY Combinator Launches of the Week
- IndependentInfera, YC Company Profile
- IndependentTroy Zhang comes out of stealth mode and debuts Infera
- Public recordForm D, Infera Health, Inc., CIK 0002061090
- CompanyInfera Health website, home and about pages
- Public recordInfera AI company profile
- IndependentInfera funding and investors listing
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
